Presentation Scheduled for Monday, March 17th at 11:30am ET
NEW YORK, March 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, and Eric Grossman, MD, the Company's Vice President, Medical Affairs, are scheduled to present at the Cowen and Company Health Care Conference being held in Boston.
The presentation, which will take place on Monday, March 17th at 11:30am ET, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important, novel pharmaceutical products for
the treatment of life-threatening diseases, including renal disease and
cancer. Keryx is developing ZerenexTM (ferric citrate), an oral, iron-based
compound that has the capacity to bind to phosphate and form non-absorbable
complexes. Zerenex is currently in Phase 2 clinical development for the
treatment of hyperphosphatemia (elevated phosphate levels) in patients with
end-stage renal disease, or ESRD. The Company is also developing KRX-0401
(perifosine), a novel, potentially first-in-class, oral anti-cancer agent
that modulates Akt, a protein in the body associated with tumor survival
and growth. KRX-0401 also modulates a number of other key signal
transduction pathways, including the JNK and MAPK pathways, which are
pathways associated with programmed cell death, cell growth, cell
differentiation and cell survival. KRX-0401, which is currently in Phase 2
clinical development for multiple tumor types, is expected to move into a
Phase 3 clinical program in 2008. The Company also has an active
in-licensing and acquisition program designed to identify and acquire
additional drug candidates. Keryx is headquartered in New York City.
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved